Registry-listed formulations

This catalogue entry has no confirmed scientific concept.

Each study is counted once in the molecule profile. Registry products remain separate. Naming an ingredient does not establish that products are interchangeable or what participants received.

1 source entries across 1 studies. This list may not include all unresolved or historical entries.

  • 68Ga-NOTA-anti-HER2 VHH1Registry product

    Linked study entry; product equivalence not established

    Formulation reported by source: SOLUTION FOR INJECTION

    View study and source

Success Metrics

Completion Rate
0%(0/1)
Active Trials
0(0%)
Terminated
1(33%)

Phase Distribution

Phase 2
3
100%

Phase Distribution

0

Early Stage

3

Mid Stage

0

Late Stage

Phase Distribution3 total trials
Phase 2Efficacy & side effects
3(100.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

0.0%

0 of 1 finished

Non-Completion Rate

100.0%

1 ended early

Currently Active

0

trials recruiting

Total Trials

3

all time

Status Distribution
Terminated(1)
Other(2)

Detailed Status

unknown2
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
3
Active
0
Success Rate
0.0%
Most Advanced
Phase 2

Trials by Phase

Phase 23 (100.0%)

Trials by Status

terminated133%
unknown267%

Recent Activity

0 active trials
Showing 3 of 3
terminatedphase_2

Evaluation of 68-GaNOTA-Anti-HER2 VHH1 Uptake in Brain Metastasis of Cancer Patients

NCT03331601
unknownphase_2

Repeatability of 68-GaNOTA-Anti-HER2 VHH1 PET/CT in Breast Carcinoma Patients

NCT03924466
unknownphase_2

Evaluation of 68GaNOTA-Anti-HER2 VHH1 uptake in brain metastasis of cancer patients

SYF46d35c8704914d938f11e28912871686

Clinical Trials (3)

Showing 3 of 3 trials
NCT03331601Phase 2

Evaluation of 68-GaNOTA-Anti-HER2 VHH1 Uptake in Brain Metastasis of Cancer Patients

Terminated
NCT03924466Phase 2

Repeatability of 68-GaNOTA-Anti-HER2 VHH1 PET/CT in Breast Carcinoma Patients

Unknown
SYF46d35c8704914d938f11e28912871686Phase 2

Evaluation of 68GaNOTA-Anti-HER2 VHH1 uptake in brain metastasis of cancer patients

Unknown

All 3 trials loaded

Drug Details

Intervention Type
Drug
Total Trials
3